SCHEMBL24334356

SCHEMBL24334356

CC1CCN1c1cc(F)c2cc(C(=O)NSc3ccccc3-c3ccccc3)oc2c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 4/20 0.34
CHRM1 P11229 2/20 0.34
MAPK1 P28482 1/20 0.33
MCHR1 Q99705 2/20 0.33
KCNH2 Q12809 1/20 0.33
PIK3C3 Q8NEB9 1/20 0.33
TP53 P04637 1/20 0.32
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
KMT2A Q03164 1/20 0.31
ATM Q13315 1/20 0.31
ACHE P22303 3/20 0.31
DPP4 P27487 1/20 0.31
MAOB P27338 3/20 0.31
HTR7 P34969 1/20 0.31
ALOX5 P09917 1/20 0.31
MAOA P21397 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
CHRM5 P08912 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24333731 0.87 CHRM2 (0.37) CHRM2CHRM1MAPK1MCHR1KCNH2
SCHEMBL24333739 0.84 HTR7 (0.36) CHRM2CHRM1MCHR1KCNH2TP53
SCHEMBL24334448 0.83 CCR3 (0.32)
SCHEMBL29469717 0.82 ALOX5AP (0.36) CHRM2CHRM1MEN1ALDH1A1KMT2A
SCHEMBL24334359 0.82 ALOX5AP (0.36) CHRM2CHRM1MEN1ALDH1A1KMT2A
SCHEMBL24334358 0.81 ALDH1A1 (0.36) TP53MEN1ALDH1A1KMT2ANPC1
SCHEMBL24333729 0.78 HPGD (0.39) CHRM2CHRM1MCHR1KCNH2MEN1
SCHEMBL29469819 0.78 HPGD (0.39) CHRM2CHRM1MCHR1KCNH2MEN1
SCHEMBL24334197 0.77 MCL1 (0.35) CHRM2CHRM1MEN1ALDH1A1KMT2A
SCHEMBL29469829 0.77 MCL1 (0.35) CHRM2CHRM1MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed